application filed with the FDA, for PTSD treatment in assisted therapy (not as a prescription)

https://mapsbcorp.com/news/mdma-for-ptsd-fda-submission/

@MatthewBaggott It seems like this question would be more interesting if trading were left open until June 1 2024. Should we extend the close date? Was the early closing date intentional?

https://maps.org/2023/09/13/maps-pbc-publishes-results-of-successful-confirmatory-phase-3-trial-of-mdma-assisted-therapy-for-ptsd/

"MAPS PBC is compiling data from 18 MAPS-sponsored Phase 2 and Phase 3 studies to form the basis of the New Drug Application, expected to be filed with the FDA later this year [2023]. "

MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD - Multidisciplinary Association for Psychedelic Studies - MAPS

FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and administered by MAPS Public Benefit Corporation (MAPS PBC), a subsidiary of MAPS. MAPS PBC is… Continue reading MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD

@EliGaultney and then at the end of all of that, if the DEA feels like it, they can just go "hmm... no."